Two doses for children and adolescents; one or two for susceptible adults.
PRIORIX-TETRA is listed under Health Canada DIN 02297884. The product record and monograph below describe this formulation; the dose schedule comes from the Canadian Immunization Guide.
At a glance
Brand
PRIORIX-TETRA
DIN
02297884
Vaccine
Measles, mumps, rubella, varicella — live attenuated
Presentation
0.5 mL · powder for solution · subcutaneous or intramuscular · 12 months to 12 years
Live vaccine
Yes
Age and suitability depend on the product, the person and the reason for vaccination. Use the planner for a starting point and confirm with a healthcare professional.
Official sources
Use the DIN to confirm this exact product in Health Canada's Drug Product Database.
A listed product may not be stocked or publicly funded.
Before and after your vaccination
Bring your immunization record if you have one, so earlier doses can be checked.
Tell the healthcare professional about a serious reaction to a previous vaccine or an ingredient, and mention any health conditions or medicines that could affect your vaccination.
After the dose, stay where you can be observed for at least 15 minutes. Tell someone right away if you feel faint or develop symptoms of an allergic reaction.
Keep a record of the vaccine name, date and dose you received.
For product-specific effects and precautions, check this DIN in the Health Canada product record and monograph. The general appointment steps above apply to all vaccinations.
No directly matching Pharmasist product guide was identified for this DIN. Use the linked Health Canada record to check your exact product.
Dose schedules
These are Canadian Immunization Guide schedules associated with this DIN. The right schedule depends on age, health, prior doses and reason for vaccination. Public health recommendations may differ from a product monograph's authorized schedule.
MMRV — children, two doses (12 months to 12 years)
2 doses
Dose 1 at 12 to 15 months and dose 2 at 18 months or later; not used at 13 years and older.
Combined measles-mumps-rubella-varicella vaccine is authorized for healthy children 12 months to less than 13 years. First dose at 12 to 15 months, second at 18 months or later but before school entry. Minimum interval 4 weeks (3 months recommended for the varicella component). Febrile seizures are slightly more common after a first dose of MMRV than separate MMR and varicella vaccines in 12 to 23 month olds.
Family guidance on pregnancy: Generally contraindicated: MMR and MMRV are live vaccines. Avoid pregnancy for 4 weeks after a dose. Vaccination may be considered during a measles or rubella outbreak.
Family guidance on breastfeeding: Recommended if not immune.
General information only. A suggested date is not an appointment or a prescription; a healthcare professional confirms what you need. Clinical rules reviewed on 2026-09-27.